Rare diseases
Investigational molecules
Locations
3115 Merryfield Row Suite 110, 92121-1174, United States
858 Therapeutics Inc. concentrates its research efforts on developing novel treatments for malignant neoplasms, with particular emphasis on solid tumor pathologies. The company's investigational programs target advanced-stage cancers where current therapeutic options remain limited, addressing critical unmet medical needs in the oncology treatment landscape.
The sponsor's research portfolio reflects a commitment to advancing precision medicine approaches in cancer care, with clinical investigations spanning multiple international sites to evaluate the safety and efficacy of innovative oncologic compounds in patient populations with difficult-to-treat malignancies.
858 Therapeutics Inc. runs clinical trials in conditions such as Breast cancer, Neoplasm malignant, Hormone-refractory prostate cancer, Ovarian epithelial cancer, among others.
Clinical trials run by this sponsor – those enrolling participants first.
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
